Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Q3 2026
Arcturus Therapeutics Holdings (ARCT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Arcturus Therapeutics Holdings (ARCT) reported revenue of $18.3M for the third quarter 2026 (Q3 2026), +7% from a year earlier and +518% from the quarter before. Operating margin was -50.2%, net loss $7.4M (40.5% of revenue).
Arcturus Therapeutics Holdings, Q3 2026: revenue $18.3M (+7% year over year), operating margin -50.2%, net loss $7.4M, operating cash flow −$6.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.3M | +518% | +7% |
| Operating profit | −$9.2M | — | — |
| Net earnings | −$7.4M | — | — |
| Operating cash flow | −$6.9M | — | — |
What changed
Revenue was $18.3M in Q3 2026, up 7% year over year and up 518% from the previous quarter. Collaboration Revenue was the largest line at 92% of revenue. Collaboration Revenue added $2.7M year over year (up 19%), 236% of the total change. Grant declined 52%.
Operating costs exceeded revenue by $9.2M, an operating margin of -50.2%. Total costs fell 18% while revenue rose 7%. The quarter ended with a net loss of $7.4M, narrower than the previous quarter's $23.8M loss. Non-operating items added $1.8M, -24% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$6.9M. Non-cash charges added back $600K of depreciation and amortization and $4.0M of share-based compensation. Working capital and other items used $4.1M. Capital expenditures of $52K exceeded it, leaving free cash flow of −$7.0M.
Questions
What was Arcturus Therapeutics Holdings' revenue in the third quarter 2026?
Arcturus Therapeutics Holdings (ARCT) reported revenue of $18.3M for the third quarter 2026 (Q3 2026), +7% from a year earlier and +518% from the quarter before.
Was Arcturus Therapeutics Holdings profitable in the third quarter 2026?
Operating loss was $9.2M (-50.2% of revenue) and net loss $7.4M.